Therapeutics , Targets , and Chemical Biology Tasquinimod Is an Allosteric Modulator of HDAC 4 Survival Signalingwithin theCompromisedCancerMicroenvironment

Tasquinimod is an orally active antiangiogenic drug that is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer. However, the target of this drug has remained unclear. In this study, we applied diverse strategies to identify the histone deacetylase HDAC4 as a target for the antiangiogenic activity of tasquinimod. Our comprehensive analysis revealed allosteric binding (Kd 10–30 nmol/L) to the regulatory Zn2þ binding domain of HDAC4 that locks the protein in a conformation preventing HDAC4/N-CoR/HDAC3 complex formation. This binding inhibited colocalization of N-CoR/HDAC3, thereby inhibiting deacetylation of histones and HDAC4 client transcription factors, such as HIF-1a, which are bound at promoter/enhancers where epigenetic reprogramming is required for cancer cell survival and angiogenic response. Through this mechanism, tasquinimod is effective as a monotherapeutic agent against human prostate, breast, bladder, and colon tumor xenografts, where its efficacy could be further enhanced in combination with a targeted thapsigargin prodrug (G202) that selectively kills tumor endothelial cells. Together, our findings define a mechanism of action of tasquinimod and offer a perspective on how its clinical activity might be leveraged in combination with other drugs that target the tumor microenvironment. Cancer Res; 73(4); 1386–99. 2012 AACR.

[1]  B. Halmos,et al.  Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells , 2013, Molecular carcinogenesis.

[2]  S. Christensen,et al.  Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy , 2012, Science Translational Medicine.

[3]  T. Leanderson,et al.  Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline‐3‐carboxamide tasquinimod (ABR‐215050) , 2012, The Prostate.

[4]  M. Manns,et al.  S100A9 a new marker for monocytic human myeloid‐derived suppressor cells , 2012, Immunology.

[5]  T. DeWeese,et al.  Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts , 2012, The Prostate.

[6]  T. Leanderson,et al.  S100A9 Interaction with TLR4 Promotes Tumor Growth , 2012, PloS one.

[7]  Chris T. Harvey,et al.  HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia* , 2011, The Journal of Biological Chemistry.

[8]  Euan A Stronach,et al.  HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. , 2011, Cancer research.

[9]  M. Squadrito,et al.  Macrophage regulation of tumor angiogenesis: implications for cancer therapy. , 2011, Molecular aspects of medicine.

[10]  T. Padhya,et al.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment , 2010, The Journal of experimental medicine.

[11]  J. Isaacs.  The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer , 2010, Expert opinion on investigational drugs.

[12]  Junjie Chen,et al.  Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. , 2010, Molecular cell.

[13]  K. Schroder,et al.  Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll‐like receptor 4 agonist LPS , 2010, Journal of leukocyte biology.

[14]  A. Armstrong,et al.  A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC). , 2010 .

[15]  Johan Vallon-Christersson,et al.  Open Access Research , 2022 .

[16]  Qin Li,et al.  c-Myc mediates a hypoxia-induced decrease in acetylated histone H4. , 2009, Biochimie.

[17]  L. Ellis,et al.  Targeting tumor angiogenesis with histone deacetylase inhibitors. , 2009, Cancer letters.

[18]  R. De Francesco,et al.  Loss of histone deacetylase 4 causes segregation defects during mitosis of p53-deficient human tumor cells. , 2009, Cancer research.

[19]  P. Sinha,et al.  Inflammation enhances myeloid‐derived suppressor cell cross‐talk by signaling through Toll‐like receptor 4 , 2009, Journal of leukocyte biology.

[20]  Florian Diehl,et al.  HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. , 2009, Blood.

[21]  Amy S. Lee,et al.  Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor–induced apoptosis , 2009, Molecular Cancer Therapeutics.

[22]  Jun Luo,et al.  Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.

[23]  T. Leanderson,et al.  Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides , 2009, PLoS biology.

[24]  H. Katoh,et al.  FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. , 2009, Cancer research.

[25]  V. Castronovo,et al.  HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism , 2009, Oncogene.

[26]  Eun‐Jin Kim,et al.  Transcriptional activation of hypoxia‐inducible factor‐1α by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH‐1 , 2009, FEBS letters.

[27]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[28]  M. Krstic-Demonacos,et al.  PCAF is an HIF-1α cofactor that regulates p53 transcriptional activity in hypoxia , 2008, Oncogene.

[29]  M. Bottomley,et al.  Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain* , 2008, Journal of Biological Chemistry.

[30]  S. Mousa,et al.  Cellular conditioning with trichostatin A enhances the anti‐stress response through up‐regulation of HDAC4 and down‐regulation of the IGF/Akt pathway , 2008, Aging cell.

[31]  Nicholas Denko,et al.  Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. , 2008, Mutation research.

[32]  R. Hill,et al.  The tumor microenvironment and metastatic disease , 2008, Clinical & Experimental Metastasis.

[33]  U. Koch,et al.  Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases , 2007, Proceedings of the National Academy of Sciences.

[34]  Maud Martin,et al.  Class IIa histone deacetylases: regulating the regulators , 2007, Oncogene.

[35]  J. Isaacs,et al.  The quinoline‐3‐carboxamide anti‐angiogenic agent, tasquinimod, enhances the anti‐prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts , 2007, The Prostate.

[36]  D. Qian,et al.  Identification of ABR‐215050 as lead second generation quinoline‐3‐carboxamide anti‐angiogenic agent for the treatment of prostate cancer , 2006, The Prostate.

[37]  W. Isaacs,et al.  A novel role of myosin VI in human prostate cancer. , 2006, The American journal of pathology.

[38]  Arvind P Pathak,et al.  Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. , 2006, Cancer research.

[39]  J. Isaacs,et al.  Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. , 2006, Cancer research.

[40]  G. Semenza,et al.  Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. , 2005, Blood.

[41]  H. Kato,et al.  Histone Deacetylase 7 Associates with Hypoxia-inducible Factor 1α and Increases Transcriptional Activity* , 2004, Journal of Biological Chemistry.

[42]  D. Neal,et al.  Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. , 2004, European urology.

[43]  R. Sainson,et al.  Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. , 2003, Microvascular research.

[44]  C. Chiang,et al.  Hypoxia Actively Represses Transcription by Inducing Negative Cofactor 2 (Dr1/DrAP1) and Blocking Preinitiation Complex Assembly* , 2003, The Journal of Biological Chemistry.

[45]  R. Dhir,et al.  Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  F. Dequiedt,et al.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.

[47]  D. Mottet,et al.  Site-directed mutagenesis studies of the hypoxia-inducible factor-1alpha DNA-binding domain. , 2002, Biochimica et biophysica acta.

[48]  J. Pouysségur,et al.  p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1* , 1999, The Journal of Biological Chemistry.

[49]  G. Semenza,et al.  Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[50]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.